Farr Miller & Washington’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
$2.51M Buy
3,364
+267
+9% +$200K 0.16% 62
2021
Q2
$2M Buy
3,097
+290
+10% +$176K 0.13% 67
2021
Q1
$1.6M Buy
2,807
+80
+3% +$47.4K 0.11% 77
2020
Q4
$1.59M Buy
2,727
+105
+4% +$59.8K 0.12% 67
2020
Q3
$1.35M Buy
2,622
+123
+5% +$62.3K 0.12% 69
2020
Q2
$1.13M Sell
2,499
-65
-3% -$28.7K 0.09% 74
2020
Q1
$899K Buy
2,564
+67
+3% +$24.6K 0.08% 70
2019
Q4
$924K Buy
2,497
+261
+12% +$92K 0.07% 77
2019
Q3
$744K Buy
2,236
+311
+16% +$101K 0.06% 87
2019
Q2
$602K Buy
1,925
+54
+3% +$16.2K 0.05% 92
2019
Q1
$572K Hold
1,871
0.05% 88
2018
Q4
$434K Buy
1,871
+50
+3% +$13.4K 0.04% 94
2018
Q3
$570K Buy
1,821
+20
+1% +$6.21K 0.05% 92
2018
Q2
$520K Buy
1,801
+20
+1% +$5.52K 0.05% 91
2018
Q1
$445K Buy
1,781
+55
+3% +$14K 0.04% 107
2017
Q4
$412K Hold
1,726
0.04% 107
2017
Q3
$384K Buy
1,726
+21
+1% +$4.73K 0.04% 111
2017
Q2
$386K Buy
1,705
+680
+66% +$148K 0.04% 108
2017
Q1
$204K Buy
+1,025
New +$197K 0.02% 144

Other funds holding BIO

Farr Miller & Washington's BIO Position: Q3 2021 in Review

Farr Miller & Washington increased its Bio-Rad Laboratories Class A (BIO) stake by 8.6% in Q3 2021, buying an estimated $200K and bringing the position to 3,364 shares worth $2.51M. The position accounts for 0.16% of the portfolio, ranked #62.

Farr Miller & Washington first reported a position in BIO in Q1 2017 and has held it in 19 quarters since. 507 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

  • Farr Miller & Washington held 3,364 shares of Bio-Rad Laboratories Class A worth $2.51M as of Q3 2021.
  • Farr Miller & Washington bought 267 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $200K.
  • Bio-Rad Laboratories Class A made up 0.16% of Farr Miller & Washington's portfolio in Q3 2021, its #62 holding.
  • Farr Miller & Washington first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and has held it in 19 quarters since.
  • 507 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on Farr Miller & Washington's 13F filing for Q3 2021, filed 15 Nov 2021.